Neuroblastoma (NB) is the most common extracranial solid malignancy of childhood ([Henry *et al*, 2005](#bib14){ref-type="other"}). Staging, clinical management and prognosis mainly depend on the presence/absence of bone marrow (BM) and skeletal involvement ([Brodeur *et al*, 1993](#bib4){ref-type="other"}). Almost 50% of NB patients present at diagnosis with localised disease, that is, they do not have evidence of BM metastases, as assessed by morphological examination of both marrow smears and trephine biopsies, nor other distant localisations investigated by ^123^I-MIBG scintigraphy.

Usually patients with localised disease are treated by surgery alone (stage 1 and 2) or by standard-dose chemotherapy followed by surgery (stage 3), unless amplification of the *Myc-N* proto-oncogene is detected in their tumour cells ([Rubie *et al*, 1997b](#bib27){ref-type="other"}; [Haase *et al*, 1999](#bib12){ref-type="other"}; [Simon *et al*, 2004](#bib32){ref-type="other"}; [Henry *et al*, 2005](#bib14){ref-type="other"}; [Maris, 2005](#bib19){ref-type="other"}), which requires a more aggressive chemotherapeutic regimen. Event-free (EFS) and overall (OS) survival of the patients with localised disease without *Myc-N* amplification are good (95% for stage 1, 86% stage 2 and 65% for stage 3 patients; [Cotterill *et al*, 2000](#bib10){ref-type="other"}), but a small percentage of them relapse and may die of disease.

Genetic abnormalities at chromosome 1p ([Rubie *et al*, 1997a](#bib26){ref-type="other"}), 3p, 11q ([Spitz *et al*, 2003](#bib35){ref-type="other"}; [Attiyeh *et al*, 2005](#bib2){ref-type="other"}; [Simon *et al*, 2006](#bib33){ref-type="other"}) and 17q ([Brinkschmidt *et al*, 2001](#bib3){ref-type="other"}), as well as biochemical ([Simon *et al*, 2003](#bib31){ref-type="other"}), histological ([Perez *et al*, 2000](#bib24){ref-type="other"}; [Navarro *et al*, 2006](#bib22){ref-type="other"}; [Sano *et al*, 2006](#bib29){ref-type="other"}), and biological factors ([Christiansen *et al*, 1995](#bib7){ref-type="other"}; [Cheung *et al*, 1997](#bib6){ref-type="other"}; [Kramer *et al*, 1997](#bib16){ref-type="other"}; [Perez *et al*, 2000](#bib24){ref-type="other"}; [Ladenstein *et al*, 2001](#bib18){ref-type="other"}; [Mora *et al*, 2001](#bib20){ref-type="other"}; [Krams *et al*, 2003](#bib17){ref-type="other"}; [Riley *et al*, 2004](#bib25){ref-type="other"}; [Haber *et al*, 2006](#bib13){ref-type="other"}; [Spitz *et al*, 2006](#bib34){ref-type="other"}), do not seem to have the same relevance in patients with localised NB as they do in patients with metastatic disease. Gene expression profiling and GCH studies have suggested specific favourable and unfavourable NB signatures ([Takita *et al*, 2004](#bib38){ref-type="other"}; [Ohira *et al*, 2005](#bib23){ref-type="other"}; [Vandesompele *et al*, 2005](#bib40){ref-type="other"}), but presently a widespread identification of patients at risk of relapse by these techniques cannot be envisaged. Therefore, an independent, easily applicable, prognostic marker able to identify patients that would benefit from a more careful follow-up is currently lacking.

In a previous study, aimed to assess the diagnostic and prognostic role of different techniques detection of NB tumour cells in peripheral blood and BM, we observed that in patients with localised NB the GD2 positivity in BM was negatively associated with survival ([Corrias *et al*, 2004](#bib9){ref-type="other"}). However, this finding was based on a small sample size with a relatively short follow-up. The aim of the present investigation was to evaluate the impact of BM GD2 positivity, evaluated at diagnosis by anti-GD2 immunocytochemistry (IC), and its combined effect with other known risk factors on survival of a larger cohort of patients with localised NB.

MATERIALS AND METHODS
=====================

Patients
--------

One hundred and forty-five consecutive NB patients, diagnosed with localised disease (stages 1--3) according to INSS criteria ([Brodeur *et al*, 1993](#bib4){ref-type="other"}) at 20 Italian paediatric oncology centres between January 1997 and June 2003, with available information on BM GD2 status at diagnosis, were included in the study. Disease staging ([Brodeur *et al*, 1993](#bib4){ref-type="other"}) at diagnosis, including appropriate imaging, ^123^I MIBG scintigraphy and BM evaluation, was made at the referring oncology centre and centrally reviewed at the Gaslini Institute.

Therapeutic approach for stage 1--2 patients included only surgery followed by a complete re-evaluation with appropriate imaging 1 month later. Stage 3 patients also received chemotherapy according to national or international protocols. Stage 3 and 2 *Myc-N*-amplified patients received high-dose chemotherapy, myeloablative therapy with haematopoietic stem cell rescue and local radiotherapy. In case of relapse, a complete restaging, including imaging and BM evaluation, was performed.

For each patient, demographic, clinical and follow-up data, together with information on biological characteristics and other prognostic risk factors as serum LDH, NSE and ferritin, tumour *Myc-N* amplification and 1p status ([Ambros *et al*, 2003](#bib1){ref-type="other"}), are summarised in [Table 1](#tbl1){ref-type="table"}. Data were retrieved from the Italian Neuroblastoma Registry (INBR) that collects information on clinical and biological characteristics of patients at diagnosis as treatment; follow-up is sought during protocol administration and then at least yearly after treatment discontinuation ([Conte *et al*, 2006](#bib8){ref-type="other"}). Pathology data regarding the primary tumour were not considered for this study, since information according to the criteria proposed by the International Neuroblastoma Pathology Committee (INPC) was not available for patients diagnosed before 2003.

BM analysis
-----------

In general, BM aspirations and bone trephine biopsies at both iliac crests were performed under general anaesthesia during surgical procedure on the primary tumour or during '*ad hoc*\' sedation. For morphological analysis, three May Grünwald--Giemsa-stained slides from each site were examined by an experienced cytomorphologist and centrally reviewed. Trephine biopsies were obtained by a Jamshidi needle, and only biopsies containing at least 5 mm^3^ of tissue were considered adequate for evaluation. At least 30 high-resolution fields of haematoxylin--eosin-stained sections were evaluated by an experienced pathologist and centrally reviewed.

For the purpose of this study, GD2-IC was centrally performed at the Italian NB reference laboratory, as previously described ([Corrias *et al*, 2004](#bib9){ref-type="other"}). Briefly, six cytospins, each containing 5 × 10^5^ mononuclear cells, were fixed in cold acetone and incubated with the 3F8 anti-GD~2~ mAb (kindly donated by Dr Nai-Kong Cheung, Memorial Sloan Kettering Cancer Center, New York, NY, USA). After washing, slides were incubated with a biotinylated anti-mouse antibody and developed with an avidin--alkaline phosphatase conjugate (DAKO, Copenhagen, Denmark). Enumeration of GD2-positive cells was based on both morphological and immunological criteria, according to standardised conditions ([Swerts *et al*, 2005](#bib36){ref-type="other"}). Namely, the presence of round nuclei larger than that of small lymphocytes, granular chromatic structure and scarce amount of cytoplasm were considered positive morphological criteria; strong red staining localised to the entire cell membrane and cytoplasm was the positive immunological criterion. Bone marrow samples were considered positive if at least three positive tumour cells were detected out of the 3 × 10^6^ cells analysed.

The study was approved by the Institutions\' Ethical Committees. All analyses were performed after informed consent was given from the patients themselves or their legal guardians, according to the Helsinki declaration.

Statistical analysis
--------------------

Descriptive statistics were reported as percentages for categorical variables. For continuous and counting data, medians with interquartile range (IQR) were used due to the non-normal distribution of the observations and to reduce the effect of outliers. Patients were stratified according to their BM GD2 status and comparisons of frequency data were performed by means of the *χ*^2^-test or the Fisher\'s exact test, when appropriate. The Wilcoxon Mann--Whitney test was used to compare median values, while the Spearman *ρ* coefficient was used to assess correlation between variables. Event-free survival and OS analyses were performed according to the Kaplan--Meier method and compared by the log-rank test. A *P*-value \<0.05 was considered as statistically significant. Analyses were performed using Stata for Windows statistical package (release 7.0; Stata Corporation, College Station, TX, USA).

RESULTS
=======

During the study period, 145 patients diagnosed with localised NB and registered in the INBR had their BM aspirates analysed at diagnosis by anti-GD2-IC. Patients included in the study were similar for age, sex, stage, *Myc-N* status and survival to the children with localised NB without information on GD2 status at diagnosis (see [Supplementary data](#sup1){ref-type="other"}).

Demographic, clinical, biochemical and genetic features of the 145 study patients stratified according to BM GD2-IC status are reported in [Table 1](#tbl1){ref-type="table"}. In more detail, 126 patients (86.9%) were GD2 negative and 19 (13.1%) were GD2 positive. Among the 19 GD2-positive patients ([Table 2](#tbl2){ref-type="table"}), the number of positive cells ranged between 1 and 155 (median=3; IQR 2-20) out of 10^6^ total cells examined. It is to be noted that of the 11 patients with less than five GD2-positive cells/10^6^ total cells, seven were also evaluated by RT-PCR and all but one were found to be positive for at least one NB molecular marker (data not shown). Three examples of GD2-positive samples are shown in [Figure 1](#fig1){ref-type="fig"}. As reported in [Table 1](#tbl1){ref-type="table"}, no association was found between GD2 status and each of the other risk factors considered.

Seven (36.8%) of the 19 GD2-positive patients relapsed, all locally, and four of them died due to local disease progression ([Table 2](#tbl2){ref-type="table"}). The 5-year EFS and OS of this group were 62.2 and 74.9%, respectively ([Table 1](#tbl1){ref-type="table"}; [Figure 2A and B](#fig2){ref-type="fig"}). In these patients, an inverse correlation between the number of GD2-positive cells and the time to relapse was observed (*ρ*= −0.786, *P*=0.036). Conversely, among the 126 BM GD2-negative patients, only 12 (9.5%) relapsed, 10 locally and two with metastatic disease, and five subsequently died ([Table 2](#tbl2){ref-type="table"}) with a 5-year EFS of 89.9% and an OS of 95.9% ([Table 1](#tbl1){ref-type="table"}; [Figure 2A and B](#fig2){ref-type="fig"}). Differences in EFS and OS between the two groups were significant (*P*\<0.001 and *P*=0.005, respectively; [Table 1](#tbl1){ref-type="table"}). If, as in our previous study, the five cells/10^6^ cut off was used to discriminate positive BM samples, differences in survival remained highly significant (data not shown). [Table 3](#tbl3){ref-type="table"} further reports on the 5-year EFS analyses on the entire cohort also considering other clinical and biological risk factors. A statistically significant worse effect was observed for unresectable disease (i.e., stage 3) (EFS=76.7%) *vs* resectable disease (i.e., stage 1--2) (EFS=89.8%; *P*=0.033), high LDH levels (72.1 *vs* 89.5%, *P*=0.010), *Myc-N* amplification (EFS=57.1 *vs* 90.4%, *P*\<0.001) and chromosome 1p status (EFS=45.8% for deletion, 83% for imbalance and 92.7% for normal, *P*\<0.001). The negative effect of 1p deletion remained even if 1p imbalance was pooled with the not deleted cases (data not shown); for this reason, in subsequent analyses patients with 1p imbalance were grouped with the not deleted ones.

Since *Myc-N* status directs patients towards either standard or high-risk treatment, survival analysis was repeated in patients with and without *Myc-N* amplification. In *Myc-N*-amplified patients, GD2 negativity was associated with a better survival (EFS 66 *vs* 0%), but the difference was not significant (*P*=0.073), likely due to the small number of cases. However, in *Myc-N* non-amplified patients, the BM GD2 negativity was associated with a significantly better outcome (EFS=93.2 *vs* 72.7%, *P*=0.008; [Figure 2C](#fig2){ref-type="fig"}). In the same *Myc-N*-negative patients, the combined prognostic role of GD2 and 1p status was also assessed. Patients negative for both markers had a 96.9% EFS, which was significantly better than that observed among children positive for at least one marker (EFS=66.0%; *P*\<0.001; [Figure 2D](#fig2){ref-type="fig"}). In the same group of *Myc-N*-negative patients, the OS showed a similar pattern (98% for the GD2-negative subjects *vs* 83% for the GD2-positive subjects). Finally the OS of patients positive for either GD2 or *Myc-N* was worse than that of patients negative for both the markers (83.1 *vs* 100%), but the very low number of observed deaths prevents one to draw definitive conclusions.

Finally, among BM GD2-IC-positive patients, a worse survival was found in children with ⩾20 GD2-positive cells/10^6^ total cells, corresponding to the fourth quartile (EFS=77.1 *vs* 20.0%, *P*=0.002). A similar result was also observed after excluding the two patients with *Myc-N* amplification (data not shown).

Because of the small sample size (19 BM GD2-positive patients) and low number of events, results from a multivariate analysis should be taken with caution and are herewith reported only as [Supplementary data](#sup1){ref-type="other"}. In this analysis, the GD2-IC status seemed to maintain its prognostic role independently from both *Myc-N* amplification and 1p deletion. It is of note that conversely *Myc-N* amplification and 1p deletion were indeed correlated, being 72.7% of *Myc-N* amplified patients also deleted of 1P.

DISCUSSION
==========

This study has confirmed our previous observation ([Corrias *et al*, 2004](#bib9){ref-type="other"}) of a negative impact of BM GD2-positive cell infiltration on survival of patients with localised NB. In particular, in this larger cohort of patients with a longer follow-up, we have shown that this effect is not due to the association with other risk factors as *Myc-N* amplification and 1p deletion.

Other reports have previously documented that tumour cells may be detected by IC and/or RT-PCR in BM of children with localised NB ([Moss *et al*, 1991](#bib21){ref-type="other"}; [Cheung *et al*, 1998](#bib5){ref-type="other"}; [Trager *et al*, 2003](#bib39){ref-type="other"}; [Corrias *et al*, 2004](#bib9){ref-type="other"}; [Simon *et al*, 2004](#bib32){ref-type="other"}; [Ifversen *et al*, 2005](#bib15){ref-type="other"}; [Russell *et al*, 2005](#bib28){ref-type="other"}; [Swerts *et al*, 2006](#bib37){ref-type="other"}). However, the limited number of patients analysed and/or the short follow-up of those studies did not allow one to draw definitive conclusions on the prognostic impact of this detection. In addition, a large multi-centre European study ([Navarro *et al*, 2006](#bib22){ref-type="other"}) and several other national studies ([Christiansen *et al*, 1995](#bib7){ref-type="other"}; [Cheung *et al*, 1997](#bib6){ref-type="other"}; [Ladenstein *et al*, 2001](#bib18){ref-type="other"}; [Simon *et al*, 2003](#bib31){ref-type="other"}; [Sano *et al*, 2006](#bib29){ref-type="other"}; [Spitz *et al*, 2006](#bib34){ref-type="other"}) have indicated that stage and *Myc-N* status were the only independent risk factors for children with localised NB. However, *Myc-N* amplification is a relatively rare event, occurring, as in our series, in about 10% of localised NB patients ([Haase *et al*, 1999](#bib12){ref-type="other"}; [Perez *et al*, 2000](#bib24){ref-type="other"}; [Henry *et al*, 2005](#bib14){ref-type="other"}; [Maris, 2005](#bib19){ref-type="other"}) and is thus inadequate to identify all the patients who will eventually relapse.

A negative prognostic role of unfavourable histology ([Perez *et al*, 2000](#bib24){ref-type="other"}), of 11q LOH ([Attiyeh *et al*, 2005](#bib2){ref-type="other"}; [Simon *et al*, 2006](#bib33){ref-type="other"}), and of a specific GCH profile ([Schleiermacher *et al*, 2007](#bib30){ref-type="other"}), was also previously reported in patients with localised disease. This effect was independent from *Myc-N* status. Unfortunately, homogeneous information on tumour histology (i.e., INPC classification) was not available in our registry because of the long recruitment period covered by this study. Moreover, our patients were not screened for genetic abnormalities other than *Myc-N* amplification and 1p deletion. Even if genetic screening could have been more precise, our observation of a negative prognostic role of BM GD2-IC positivity suggests that also this technique, which has become accurate, thanks to recent standardisation ([Swerts *et al*, 2005](#bib36){ref-type="other"}), might be of interest in future studies.

The low relapse rate observed in our cohort is similar to that expected in patients with localised NB, and indicates that staging was correct. The fact that presence of GD2-positive cells in the BM correlated with a higher tendency of relapse at the primary site, instead that in the BM, is surprising. However, also [Perez *et al* (2000)](#bib24){ref-type="other"} did not observe further BM involvement in eight stage 1--2 patients found positive by BM immunocytology. Thus, it is conceivable that the very few GD2-positive cells, detected by IC at diagnosis, were unable to survive and actively proliferate in the BM. Whether this inability to invade the marrow compartment was related to the NB cells themselves or to the presence/absence of factors in the BM microenvironment ([Fidler, 2003](#bib11){ref-type="other"}) remains to be determined in future studies.

Our observation that higher number of GD2-positive cells correlated with poorest survival and with a shorter time to relapse is similar to that previously reported by [Moss *et al* (1991)](#bib21){ref-type="other"}. Even if this finding was based on a very small sample size (i.e., seven relapses in GD2-positive patients), it suggests that quantification by IC might add useful clinical information and that BM GD2-IC positivity reflects a biological feature of the neuroblasts that can affect the disease course.

In our study, survival analysis on other prognostic factors confirmed the negative role of *Myc-N* amplification, high LDH serum levels and 1p deletion. Only a multivariable analysis based on a larger series will be able to assess the combined effect of BM GD2 positivity and the other known major risk factors. However, our data suggest that in patients with localised disease without *Myc-N* amplification, the combination of BM GD2-IC and 1p status might help individuating those at risk of relapse.

In conclusion, we believe that BM GD2-IC analysis might have the potential to discriminate different risk groups within localised NB patients. In fact, GD2-IC seems to provide additional information on biological features and has the advantage of generating quantitative data. We neither recommend that BM GD2-IC status be used for staging purposes, nor the patient be shifted to a more intensive treatment because not all the GD2 positive patients relapsed. However, in future multi-national studies, patients with localised disease should be evaluated by GD2-IC. In fact, in the presence of BM GD2-positive cells, especially if combined with chromosome 1p deletion, patients should be closely followed, and in case of relapse, they should be treated more aggressively.
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![Cytospin of BM aspirates fixed in acetone and immunologically stained with anti-GD2 antibody. (**A**, **B**) Rosettes of NB cells stained in red, from patients F/18 and F/8, respectively; (**C**) a single NB cell stained in red from patient M/73; (**D**) a completely negative aspirate. Magnification is × 40.](6604179f1){#fig1}

![(**A**) Event-free survival of patients with localised NB stratified by BM GD2-IC status. (**B**) Overall survival of patients with localised NB stratified by GD2-IC status. (**C**) Event-free survival of patients with normal *Myc-N* status stratified by GD2-IC status. (**D**) Event-free survival of patients with normal *Myc-N* status stratified by GD2-IC and chromosome 1p status.](6604179f2){#fig2}

###### 

Demographic, clinical, biochemical and genetic features of the 145 patients with localised NB stratified by GD2 status

                            **GD2 negative (*n*=126)**   **GD2 positive (*n*=19)**        **Total (*n*=145)**                  
  ------------------------ ---------------------------- --------------------------- ---- --------------------- --------- ----- ------
  *Gender*                                                                                                       0.059            
   Male                                 69                         54.8              6           31.6                     75    51.7
   Female                               57                         45.2              13          68.4                     70    48.3
                                                                                                                                  
  *Age*                                                                                                          0.932            
   \<12 months                          61                         48.4              9           47.4                     70    48.3
   ⩾12 months                           65                         51.6              10          52.6                     75    51.7
                                                                                                                                  
  *Primary site*                                                                                                 0.923            
   Neck                                 7                           5.6              0            0.0                      7    4.8
   Thorax                               29                         23.0              4           21.1                     33    22.8
   Abdomen, adrenal                     44                         34.9              7           36.8                     51    35.2
   Abdomen, other sites                 46                         36.5              8           42.1                     54    37.2
                                                                                                                                  
  *INSS stage*                                                                                                   0.315            
   Stage 1                              59                         46.8              7           36.8                     66    45.5
   Stage 2                              35                         27.8              4           21.1                     39    26.9
   Stage 3                              32                         25.4              8           42.1                     40    27.6
                                                                                                                                  
  *NSE (78 tested)*                                                                                              0.660            
   \<100 ng ml^−1^                      57                         89.1              12          85.7                     69    88.5
   ⩾100 ng ml^−1^                       7                          10.9              2           14.3                      9    11.5
                                                                                                                                  
  *LDH (123 tested)*                                                                                             0.999            
   \<1000 IU ml^−1^                     86                         81.9              15          83.3                     101   82.1
   ⩾1000 IU ml^−1^                      19                         18.1              3           16.7                     22    17.9
                                                                                                                                  
  *Ferritin (95 tested)*                                                                                         0.999            
   \<150 ng ml^−1^                      63                         77.8              11          78.6                     74    77.9
   ⩾150 ng ml^−1^                       18                         22.2              3           21.4                     21    22.1
                                                                                                                                  
  *Myc-N (124 tested)*                                                                                           0.999            
   Not amplified                        95                         88.8              15          88.2                     110   88.7
   Amplified                            12                         11.2              2           11.8                     14    11.3
                                                                                                                                  
  *1p36 (105 tested)*                                                                                            0.999            
   Not deleted                          60                         67.4              11          68.8                     71    67.6
   Deleted                              14                         15.7              2           12.5                     16    15.2
   Imbalance                            15                         16.9              3           18.8                     18    17.1
                                                                                                                                  
  5-year EFS                           126                         89.9              19          62.2           \<0.001           
  5-year OS                            126                         95.9              19          74.9            0.005            

EFS=event-free survival; NB=neuroblastoma; OS=overall survival.

###### 

Features of the GD2-positive patients and of the GD2-negative patients who relapsed

  **Stage**    **Sex/age (months)**   **GD2+ cells/10^6^ total**  **Tumour site**    **LDH** **(IU ml^−1^)**  ***Myc-N***   **1p**       **Relapse (months)**  **Type of relapse**   **Follow-up^a^**
  ----------- ---------------------- ---------------------------- ----------------- ------------------------- ------------- ----------- ---------------------- --------------------- ------------------
  1                    M/45                      1.3              Thorax                       650            Normal        Normal               ---           ---                   CR
  1                    F/2                       1.0              Abdomen                      475            Normal        Normal               ---           ---                   CR
  1                    M/25                      2.2              Pelvis                       523            Normal        Normal               ---           ---                   CR
  1                    F/93                      1.6              Thorax                       601            Normal        Normal               ---           ---                   CR
  1                    F/2                       3.0              Abdomen                      411            ND            ND                   ---           ---                   CR
  1                    M/2                       10.0             Abdomen                      494            Normal        Normal               ---           ---                   CR
  1                    M/6                       39.3             Abdomen                     1961            Amplified     Deleted              1.8           Local                 DPD
                                                                                                                                                                                      
  1                    F/10                    Negative           Abdomen                     1693            Amplified     Deleted              1.4           Local+Met             DPD
  1                    F/25                    Negative           Thorax                       617            ND            ND                   18.0          Local                 AWD
  1                    F/1                     Negative           Abdomen                      NE             Normal        Normal               10.0          Local+Met             AWD
                                                                                                                                                                                      
  2                    F/59                      8.0              Abdomen                      339            Normal        ND                   ---           ---                   CR
  2                    F/3                       2.0              Abdomen                      336            Normal        Imbalance            ---           ---                   CR
  2                    F/10                      2.0              Abdomen                      484            Gain          Normal               24.0          Local                 DPD
  2                    F/6                       3.3              Abdomen                      949            Normal        Normal               15.0          Local                 CR
                                                                                                                                                                                      
  2                    F/43                    Negative           Abdomen                      NE             Normal        Deleted              30.0          Local                 CR
  2                    M/7                     Negative           Abdomen                     1481            Normal        ND                   3.8           Local                 CR
  2                    F/11                    Negative           Neck                         444            Normal        Imbalance            25.1          Local                 AWD
  2                    M/1                     Negative           Abdomen                      409            Normal        Deleted              5.0           Local                 DPD
  3                    M/15                      2.0              Thorax                       477            Normal        Imbalance            ---           ---                   CR
                                                                                                                                                                                      
  3                    F/50                      4.5              Abdomen                      735            Normal        Deleted              ---           ---                   CR
  3                    F/15                      5.0              Abdomen                     1051            Normal        Normal               ---           ---                   CR
  3                    F/6                       20.0             Abdomen                      791            Normal        Normal               ---           ---                   CR
  3                    F/8                       34.6             Abdomen                      437            Normal        Normal               8.1           Local                 CR
  3                    F/31                      29.1             Abdomen                     2445            Amplified     ND                   13.3          Local                 DPD
  3                    F/18                     155.0             Abdomen                      ND             Normal        Normal                1            Local                 DPD
  3                    M/73                      1.0              Thor/Abd                     800            ND            Imbalance            13.2          Local                 CR
                                                                                                                                                                                      
  3                    F/11                    Negative           Abdomen                     6247            Amplified     Deleted              7.0           Local                 DPD
  3                   F/118                    Negative           Abdomen                      127            ND            Imbalance            7.0           Local                 AWD
  3                    M/17                    Negative           Abdomen                     4672            Amplified     Deleted              1.0           Local                 DPD
  3                    M/13                    Negative           Neck                         536            Amplified     Deleted              14.0          Local                 DPD
  3                    M/7                     Negative           Abdomen                      401            Normal        Deleted              17.0          Local                 CR

AWD=alive with disease; CR=complete remission; DPD=dead of progressive disease; F=female; M=male; ND=not determined.

###### 

EFS of patients with localised NB stratified according to the indicated variables

  **Variables**             ***n***   **5-year EFS %**   **s.e.^a^**   ***P***
  ------------------------ --------- ------------------ ------------- ---------
  *GD2*                                                                \<0.001
   Negative                   126           89.9            0.03           
   Positive                   19            62.2            0.36           
                                                                           
  *Gender*                                                              0.166
   Male                       70            90.5            0.03           
   Female                     75            81.2            0.05           
                                                                           
  *Age*                                                                 0.352
   \<12 months                70            83.6            0.05           
   ⩾12 months                 75            88.7            0.04           
                                                                           
  *Primary site*^b^                                                     0.211
   Abdomen                    105           84.1            0.04           
   Thorax                     40            91.6            0.05           
                                                                           
  *Tumour stage (INSS)*                                                 0.033
   Stages 1--2                105           89.8            0.03           
   Stage 3                    40            76.7            0.07           
                                                                           
  *NSE (78 tested)*                                                     0.445
   \<100 ng ml^−1^            69            86.1            0.04           
   ⩾100 ng ml^−1^              9            77.8            0.14           
                                                                           
  *LDH (123 tested)*                                                    0.010
   \<1000 IU ml^−1^           101           89.5            0.03           
   ⩾1000 IU ml^−1^            22            72.1            0.10           
                                                                           
  *Ferritin (95 tested)*                                                0.604
   \<150 ng ml^−1^            74            84.4            0.04           
   ⩾150 ng ml^−1^             21            80.0            0.09           
                                                                           
  *Myc-N (124 tested)*                                                 \<0.001
   Not amplified              110           90.4            0.03           
   Amplified                  14            57.1            0.13           
                                                                       \<0.001
  *1p36 (105 tested)*                                                      
   Not deleted                71            92.7            0.03           
   Deleted                    16            45.8            0.14           
   Imbalance                  18            83.0            0.09           

EFS=event-free survival; NB=neuroblastoma.

Standard error.

Abdomen=adrenal+other abdominal site; thorax=thorax+neck.

[^1]: MV Corrias, S Parodi and R Haupt equally contributed as first authors.

[^2]: A Garaventa and L Faulkner equally contributed as last authors.
